Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|August 10, 2002
In vitro studies with bendamustine: enhanced activity in combination with rituximabMathias J Rummel, Kai U Chow, Dieter Hoelzer, et al.
Leukemia & Lymphoma|April 6, 2004
Altered apoptosis pathways in mantle cell lymphomaMathias J Rummel, Sven de Vos, Dieter Hoelzer, et al.
European Journal of Haematology|October 12, 2011
Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)Abderrahim Najaoui, Tamam Bakchoul, Johanna Stoy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 1999
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II studyM J Rummel, G Käfer, M Pfreundschuh, et al.
Investigational New Drugs|December 21, 2007
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen, Andreas Engert, Florian Weissinger, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 11, 2013
[Effect of systematic information about psychosocial support services during outpatient radiotherapy. A controlled trial]R O Schiel, W Herzog, H Hof, et al.
Cancers|November 14, 2023
Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384)Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, et al.
Translational Psychiatry|June 22, 2016
Paradoxical augmented relapse in alcohol-dependent rats during deep-brain stimulation in the nucleus accumbensR Hadar, V Vengeliene, E Barroeta Hlusicke, et al.
British Journal of Haematology|May 11, 2021
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)Mathias J Rummel, Ann Janssens, David MacDonald, et al.
Annals of Hematology|October 24, 2000
Induction of apoptosis using 2',2' difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cellsK U Chow, J Ries, E Weidmann, et al.
Pageof 5